Healthequity Research Coverage Started at Robert W. Baird (HQY)
Research analysts at Robert W. Baird assumed coverage on shares of Healthequity (NYSE:HQY) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $22.00 price target on the stock. Robert W. Baird’s price target would suggest a potential upside of 10.72% from the stock’s previous close. The analysts noted that the move was a valuation call.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Healthequity in a research note on Monday. They set an “overweight” rating and a $25.00 price target on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Healthequity in a research note on Monday. They set an “outperform” rating on the stock. Finally, analysts at SunTrust initiated coverage on shares of Healthequity in a research note on Monday. They set a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $24.00.
Healthequity (NYSE:HQY) opened at 19.87 on Tuesday. Healthequity has a 52 week low of $16.11 and a 52 week high of $21.48. The stock has a 50-day moving average of $18.82 and a 200-day moving average of $18.82. The company has a market cap of $985.5 million and a price-to-earnings ratio of 139.18.
HealthEquity, Inc is technology-enabled services platforms that enables consumers to make healthcare saving and spending decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.